| Name | Nedocromil |
| Description | Nedocromil (FPL 59002) inhibits the action or formation of multiple mediators. Which including histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2). |
| In vitro | Nedocromil suppresses the release of histamine, LTC4, and PGD2 from mast cells challenged with antigen with IC30 values of 2.1 μM, 2.3 μM, and 1.9 μM, respectively. It also has anti-human IgE with IC30 values of 4.7 μM, 1.3 μM, and 1.3 μM, respectively[1]. |
| In vivo | Nedocromil can obviously improve cardiac function in mice with diabetic cardiomyopathy, but the treatment cannot restore normal function. Nedocromil-treated diabetic mice display obviously improved heart function compared with controls. However, the cardiac function of Nedocromil-treated diabetic mice remains significantly impaired when compared with normal mice [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 1 mg/mL (2.69 mM), Sonication is recommended.
|
| Keywords | ProstaglandinReceptor | Prostaglandin Receptor | prostaglandin D2 receptor | PGD2 | Nedocromil | LTC4 | LeukotrieneReceptor | Leukotriene Receptor | leukotriene C4 (LTC4) | Inhibitor | inhibit | HistamineReceptor | Histamine Receptor | Histamine | FPL-59002 | FPL59002 |
| Inhibitors Related | Undecane | Tranilast | Meclizine dihydrochloride | Lidocaine | Famotidine | Rutin | Sodium butanoate | Alginic acid | Rebamipide | Mianserin hydrochloride | Trazodone hydrochloride | p-Hydroxycinnamic acid |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Human Metabolite Library | Anti-Cancer Drug Library |
United States
